SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
SABS fundamentals
SAB Biotherapeutics (SABS) released its earnings on Aug 7, 2025: revenue was 0 (YoY -100.00%), missed estimates; EPS was -1.09 (YoY -37.97%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-1.09
-37.97%
Report date
Aug 7, 2025
Earnings Call
7:00 AM on Aug 7, 2025
Meeting link.EPS
Actual | 0.2 | -1.1 | -1 | -3.38 | -0.54 | -0.79 | -1.12 | -1.23 | -0.56 | -1.09 |
Forecast | -1.4333 | -1.3 | -1.1667 | -0.62 | -0.96 | -1.1467 | -1.106 | -1.164 | -1.0725 | -0.796 |
Surprise | +113.95% | +15.38% | +14.29% | -445.16% | +43.75% | +31.11% | -1.27% | -5.67% | +47.79% | -36.93% |
Revenue
Actual | 11.80M | 6.35M | 633.50K | 300.00K | 944.58K | 300.00K | 0 | 100.00K | 0 | 0 |
Forecast | 11.47M | 10.80M | 11.97K | 0 | 0 | 0 | 120.00K | 120.00K | 125.00K | 125.00K |
Surprise | +2.92% | -41.19% | +5194.17% | 0.00% | 0.00% | 0.00% | -100.00% | -16.67% | -100.00% | -100.00% |
Earnings Call
You can ask Aime
What is SAB Biotherapeutics's gross profit margin?Did SAB Biotherapeutics beat or miss consensus estimates last quarter?What were the key takeaways from SAB Biotherapeutics's earnings call?What does SAB Biotherapeutics do and what are its main business segments?What is SAB Biotherapeutics's latest dividend and current dividend yield?What factors drove the changes in SAB Biotherapeutics's revenue and profit?What guidance did SAB Biotherapeutics's management provide for the next earnings period?What is the market's earnings forecast for SAB Biotherapeutics next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
